Early Phase 1 Head and Neck Cancer Trial, Recruiting NCT06579248 Sponsor: Henry Ford Health System Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Early Phase 1 Head and Neck Cancer Trial, Recruiting

NCT06579248
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with a specific type of throat/voice box cancer (squamous cell carcinoma of the larynx) that is at an advanced local stage and are being treated with both radiation therapy and chemotherapy together as your main treatment.
  • You are 18 years of age or older.
  • You are generally able to carry out daily activities with little to no limitation from your illness (confirm with trial site if unsure about your activity level).
  • You are willing and able to sign a consent form and fill out questionnaires about side effects and quality of life (verbal answers recorded on the form are also acceptable).
  • Your chemotherapy treatment includes at least one of these drugs: cisplatin, carboplatin, or cetuximab.

Who may not be able to join:

  • You are already receiving any other treatment specifically aimed at reducing taste problems.
  • Your cancer has spread to other parts of the body (metastatic disease).
  • You have known allergies or sensitivities to the materials used in the mouth device used in this trial.
  • You have previously received chemotherapy or radiation therapy for a head or neck cancer.
  • You are unwilling or unable to use the mouth device involved in this trial.
  • You are a current smoker or have smoked cigarettes within the 3 months before starting treatment.
  • You are unable to complete the required forms (note: verbal responses recorded daily are acceptable).
  • You have a serious uncontrolled illness, such as a severe ongoing infection requiring IV antibiotics for more than 30 days, heart failure, unstable chest pain, certain heart rhythm problems, a weakened immune system, significant liver disease, significant blood disorders, or a serious unstable mental health condition.
  • You are currently taking certain specific medications that cannot be safely switched to an alternative during the study, including: acetazolamide, maribavir, eszopiclone, topiramate, captopril, lithium, procainamide, terbinafine, or amiodarone (confirm with trial site if you take any of these).
  • You already have taste loss at the start of the study, as assessed at your first visit.
  • You have tested positive for COVID-19 during the study period.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Phone: 313-556-8422

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Sponsor
Henry Ford Health System
Registry
ClinicalTrials.gov
Start date
12 November 2024
Est. completion
30 August 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in Dysgeusia

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov